The answer to this inquiry is “yes” — but maybe “no.” Will confidentiality agreements shield any prior art concerns? Once ...

with a focus on Phase II and III trial design and challenges with rare disease research, while another will have experts from ...

Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian ...

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces that the first patient has been enrolled in the Phase 1 clinical trial of its drug candidate 177Lu ...

Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial ...

The Phase 2 trial is a multi-center ... the company has rapidly achieved significant clinical and regulatory milestones, including receiving FDA orphan drug designation for MB-105 in January 2025, ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...